In vivo study on the effects of alpha1-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs.

[1]  G. Tsujimoto,et al.  α1‐Adrenoceptors are required for normal male sexual function , 2007 .

[2]  M. Sasamata,et al.  Relationship between the functional effect of tamsulosin and its concentration in lower urinary tract tissues in dogs. , 2007, Biological & pharmaceutical bulletin.

[3]  Y. Homma,et al.  Silodosin, a new α1A‐adrenoceptor‐selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo‐controlled, double‐blind study in Japanese men , 2006, BJU international.

[4]  T. Tsukamoto,et al.  Ejaculatory disorder caused by alpha‐1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission , 2006, International journal of urology : official journal of the Japanese Urological Association.

[5]  G. Tsujimoto,et al.  Quantification of alpha1‐adrenoceptor subtypes by real‐time RT‐PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients , 2006, The Prostate.

[6]  G. Burnstock,et al.  The purinergic component of human vas deferens contraction. , 2006, Fertility and sterility.

[7]  N. Masumori,et al.  [Ejaculatory disorder by alpha-1 adrenoceptor antagonist in patients with benign prostatic hyperplasia; retrospective comparison between naftopidil and tamsulosin]. , 2005, Hinyokika kiyo. Acta urologica Japonica.

[8]  R. Mongeau,et al.  Evaluation of Tamsulosin and Alfuzosin Activity in the Rat Vas Deferens: Relevance to Ejaculation Delays , 2005, Journal of Pharmacology and Experimental Therapeutics.

[9]  I. Matsuoka,et al.  A comparative study on contractile responses of rabbit and guinea pig vasa deferentia to electrical field stimulation. , 2004, Fukushima journal of medical science.

[10]  J. Paick,et al.  In vivo rat model to measure hypogastric nerve stimulation-induced seminal vesicle and vasal pressure responses simultaneously , 2004, International Journal of Impotence Research.

[11]  M. Sasamata,et al.  Effects of tamsulosin on hypogastric nerve stimulation-induced intraurethral pressure elevation in male and female dogs under anesthesia. , 2004, European journal of pharmacology.

[12]  M. Michel,et al.  Classification of α1-adrenoceptor subtypes , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[13]  M. Williams,et al.  Preclinical pharmacology of fiduxosin, a novel alpha(1)-adrenoceptor antagonist with uroselective properties. , 2002, The Journal of pharmacology and experimental therapeutics.

[14]  P. V. Van Cangh,et al.  Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. , 2002, European urology.

[15]  F. Debruyne,et al.  Alpha blockers: are all created equal? , 2000, Urology.

[16]  T. D. de Reijke,et al.  Tamsulosin 0.4 mg Once Daily: Effect on Sexual Function in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction , 1999, European Urology.

[17]  T. Taniguchi,et al.  Pharmacological analysis of the novel, selective α1‐adrenoceptor antagonist, KMD‐3213, and its suitability as a tritiated radioligand , 1999, British journal of pharmacology.

[18]  G. Tsujimoto,et al.  Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. , 1999, Japanese journal of pharmacology.

[19]  H. Lepor.  Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. , 1998, Urology.

[20]  A. Tewari,et al.  Overview of α-Blocker Therapy for Benign Prostatic Hyperplasia , 1998 .

[21]  H. Nishimatsu,et al.  Quantification and distribution of α1‐adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions , 1997, British Journal of Pharmacology.

[22]  D. Ippolito,et al.  Effect of prazosin on sperm transport in male rats. , 1997, Reproductive toxicology.

[23]  G. Tsujimoto,et al.  Quantification and distribution of α1‐adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non‐hypertrophied tissue , 1996, British journal of pharmacology.

[24]  H. Lepor,et al.  The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. , 1996, The New England journal of medicine.

[25]  G. Tsujimoto,et al.  NS-49, a novel α1a-adrenoceptor-selective agonist characterization using recombinant human α1-adrenoceptors , 1995 .

[26]  T. Takenaka,et al.  [Discovery and development of tamsulosin hydrochloride, a new alpha 1-adrenoceptor antagonist]. , 1995, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[27]  C. Chapple,et al.  Evidence for a functional α1A‐ (α1C‐) adrenoceptor mediating contraction of the rat epididymal vas deferens and an α1B‐adrenoceptor mediating contraction of the rat spleen , 1995 .

[28]  R. Lefkowitz,et al.  International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. , 1995, Pharmacological reviews.

[29]  G. Tsujimoto,et al.  Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. , 1995, European journal of pharmacology.

[30]  T. Morita,et al.  Segmental differences in the density of autonomic receptors in dog vas deferens. , 1994, Urologia internationalis.

[31]  P. Manoury,et al.  Alfuzosin, a selective α1‐adrenoceptor antagonist in the lower urinary tract , 1993 .

[32]  S. Shima.  Characterization of adrenergic receptors in membranes from the rat seminal vesicle. , 1993, Japanese journal of pharmacology.

[33]  K. Kihara,et al.  A mechanism of retrograde ejaculation after bilateral hypogastric nerve transections in the dog. , 1992, The Journal of urology.

[34]  J. Hieble,et al.  In vitro characterization of the alpha-adrenoceptors in human prostate. , 1985, European journal of pharmacology.

[35]  L. Persky,et al.  Effect of phenoxybenzamine (dibenzyline) on sexual function in man. , 1981, Urology.

[36]  M. Caine,et al.  The use of alpha-adrenergic blockers in benign prostatic obstruction. , 1976, British journal of urology.

[37]  C. Markland,et al.  The effect of pharmacological agents on ejaculation. , 1975, The Journal of urology.